Reply: Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?

Affiliations

Comment

Ganesh Raghu et al. Am J Respir Crit Care Med. 2017.

. 2017 Jan 15;195(2):271.

doi: 10.1164/rccm.201608-1610LE.

No abstract available

Comment on

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. Raghu G, et al. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm.201506-1063ST. Am J Respir Crit Care Med. 2015. PMID: 26177183
Can Bisphosphonates Prevent Vitamin K Antagonist Toxicity in Patients with Idiopathic Pulmonary Fibrosis?
Janssen R. Janssen R. Am J Respir Crit Care Med. 2017 Jan 15;195(2):269-270. doi: 10.1164/rccm.201605-1074LE. Am J Respir Crit Care Med. 2017. PMID: 28084819 No abstract available.